期刊
PHARMACOTHERAPY
卷 28, 期 11, 页码 18S-22S出版社
PHARMACOTHERAPY PUBLICATIONS INC
DOI: 10.1592/phco.28.11-supp.18S
关键词
bevacizumab; cetuximab; chemotherapy; colorectal cancer; CRC; epidermal growth factor receptors; EGFR; guidelines; metastasis; panitumumab; vascular endothelial growth factor; VEGE
During the past decade, new therapies for colorectal cancer have emerged that significantly prolong survival times. The introduction of these new agents has resulted in changes in colorectal cancer treatment patterns; clinicians are now able to optimize therapy and minimize toxicity by developing individualized patient treatment plans using a variety of agents. Biologic agents, including bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, and cetuximab and panitumumab, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, are among the new therapies now recommended by the National Comprehensive Cancer Network (NCCN) colon and rectal cancer treatment guidelines for use in first-, second-, and/or third-line colorectal cancer therapy According to the NCCN guidelines, patients with advanced or metastatic colorectal cancer who are without contraindications are candidates to receive the anti-VEGF and anti-EGFR monoclonal antibodies at some point during the treatment course.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据